FR-008-III en es it fr

FR-008-III Brand names, FR-008-III Analogs

FR-008-III Brand Names Mixture

  • No information avaliable

FR-008-III Chemical_Formula


FR-008-III RX_link

FR-008-III fda sheet


FR-008-III msds (material safety sheet)


FR-008-III Synthesis Reference

No information avaliable

FR-008-III Molecular Weight

207.269 g/mol

FR-008-III Melting Point

144 oC

FR-008-III H2O Solubility

No information avaliable

FR-008-III State


FR-008-III LogP


FR-008-III Dosage Forms

Topical solution (8%)

FR-008-III Indication

Used as a topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum.

FR-008-III Pharmacology

Ciclopirox is a broad-spectrum antifungal medication that also has antibacterial and anti-inflammatory properties. Its main mode of action is thought to be its high affinity for trivalent cations, which inhibit essential co-factors in enzymes. Ciclopirox exhibits either fungistatic or fungicidal activity in vitro against a broad spectrum of fungal organisms, such as dermatophytes, yeasts, dimorphic fungi, eumycetes, and actinomycetes. In addition to its broad spectrum of action, ciclopirox also exerts antibacterial activity against many Gram-positive and Gram-negative bacteria. Furthermore, the anti-inflammatory effects of ciclopirox have been demonstrated in human polymorphonuclear cells, where ciclopirox has inhibited the synthesis of prostaglandin and leukotriene. Ciclopirox can also exhibit its anti-inflammatory effects by inhibiting the formation of 5-lipoxygenase and cyclooxygenase.

FR-008-III Absorption

Rapidly absorbed after oral administration. Mean absorption of ciclopirox after application to nails of all twenty digits and adjacent 5 millimeters of skin once daily for 6 months in patients with dermatophytic onychomycoses was less than 5% of the applied dose. Ciclopirox olamine also penetrates into hair and through the epidermis and hair follicles into sebaceous glands and dermis.

FR-008-III side effects and Toxicity

Oral LD50 in rat is >10 ml/kg. Symptoms of overexposure include drowsiness and headache.

FR-008-III Patient Information

No information avaliable

FR-008-III Organisms Affected

Humans, other mammals, yeast and other fungi